COVID-19 and Vitamin D: Length of Hospital Stay and Mortality

Vitamin D Level: Reflections of a Public Health Issue in the COVID-19 Pandemic. Does it Affect Mortality and Length of Hospital Stay?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05221983

Enrollment

168

Registered

2022-02-03

Start date

2021-08-21

Completion date

2021-11-16

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Pandemic, Vitamin D Deficiency

Keywords

COVID-19, Vitamin D, Length of stay, Mortality

Brief summary

The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition. In this context, can the protective properties of vitamin D play an important role in this pandemic? brought with it the thought. In this study, it was aimed to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease.

Detailed description

This research was conducted to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease. For this, the approval of the Ministry of Health and then the ethics committee was obtained. For this reason, patients with positive PCR tests and hospitalized patients with vitamin D levels in their biochemistry were included in the study. The data of the patients were obtained from the medical records. Information such as age, gender, comorbidities, length of hospital stay, vitamin D level were included in the study. According to the statistical analyzes obtained from these data, it has been shown that vitamin D level has no effect on mortality and hospital stay in COVID-19 disease.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* COVID-19 PCR (Polymerase Chain Reaction) test positive * Vitamin D level in biochemical parameters * Adult patients hospitalized for COVID-19

Exclusion criteria

-Patients using drugs that may affect vitamin D absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents

Design outcomes

Primary

Measure	Time frame	Description
Level of Vitamin D	1 month later	Vitamin D levels of patients with a diagnosis of COVID-10. These results were categorized at the level of deficiency/insufficiency/normal.
Relationship between vitamin D level and mortality	1 month later	Relationship between survival and death by categorized vitamin D level.
Relationship between vitamin D level and hospital stay	1 month later	Length of hospital stay by categorized vitamin D level.

Secondary

Measure	Time frame	Description
Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality	1 month later.	Evaluation of the impact of comorbidities on survival during COVID-19 disease.

Countries

Turkey (Türkiye)

Outcome results